The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

GIP receptor agonism and the argument about direction — does this still hold?

This is a generated summary. It shows the 5 most-liked posts from a topic of 15, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
SC
s.cabreraTL223 Jun 2026#3

Building on the opening post rather than restating it.

GIP receptor biology is genuinely contested. Both agonism and antagonism have been argued to produce weight reduction, and the fact that the field can hold both positions tells you how open it is.

17 likes 1mo
PW
PharmNotes_WhitfieldTL4Pharmacist27 Jun 2026#4
bench_notes, post #2: Answering the question the opening post raises rather than the one it answers. Central versus peripheral action: GLP-1 agonism works through both central nervous system effects (appetite) and peripheral effects (gastric motility, insulin). The balance is not fully characterised. Go to post

Amylin signalling reaches satiety through a distinct receptor complex, which is the mechanistic basis for expecting an amylin analogue and an incretin agonist to add rather than overlap.

I am confident about the direction and much less about the magnitude.

32 likes in reply to #2 1mo
BA
b.aaltoTL23 Jul 2026 · edited#6
e.lehtinen, post #5: Narrowing post #4, because the general version has more than one answer. GLP-1 receptor signalling: the GLP-1 receptor is expressed on beta cells (insulin secretion), on neurons (appetite and gastric motility), and on myocardium (contractility). Different tissues respond to the same signal in different ways. Go to post

Everything in post #2 holds. The case it does not cover is the one I have.

Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide activates both GLP-1 and GIP with different affinities. The off-target effects are part of the overall pharmacology.

The part I am sure of is shorter than the part I have written.

6 likes in reply to #5 25d
KF
k.fonsecaTL2 Solution6 Jul 2026#7

Glucagon receptor agonism raises energy expenditure and promotes hepatic fat oxidation. In a triple agonist the incretin limbs offset the glycaemic consequence, which is why the combination is not self-defeating.

The number is defensible. The precision I gave it is not.

23 likes 22d
I
IbrahimoviTL2Member20 Jul 2026#12

Building on post #9 rather than restating it.

Biased agonism — where different ligands at the same receptor favour different downstream pathways — is a plausible explanation for differences between compounds in this class and is not a demonstrated one for any specific pair.

27 likes 8d

Read the full topic (15 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. Vagal afferents — I have the observation and I do not trust my interpretation of it, so I am…
KRBSKSBCD+5 9 44k 13mo
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Appetite effects: what I expected, what I found, and the gap between them. I…
EKHFSB 2 56k 16mo
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
KHBPJNNSNH+90 98 30k 22h
Biased agonism: a real phenomenon, an over-used explanation — what changed since
Biased agonism: a real phenomenon, an over-used explanation — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Biased agonism is…
EKJHROKFEK+49 56 47k 17mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
MAVSOVSKMP+52 57 25k just now

Related topics — sharing the tags long read, amylin analogues, retatrutide

TopicParticipantsRepliesViewsActivity
What we do not know about retatrutide, listed explicitly
The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Setting out what I think I know about this compound and…
FHNSOFIG+106 113 4.8k 17mo
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. Asking about amylin receptor signalling and satiety directly, because I have read four…
SGBCTNNATT+22 26 1.8k 9mo
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
RMCCYMRMJW+149 159 30k 15mo
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Appetite effects: what I expected, what I found, and the gap between them. I…
EKHFSB 2 56k 16mo
A 40-week log with the measurement method stated — what changed since
A 40-week log with the measurement method stated — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on 40-week log. It is mine, it…
PTSMTSWMBP+9 13 2.1k 9h